Introduction
Mutations in genes important in T-cell or in both T-and B-cell development and function cause severe combined immunodeficiency (CID), with a majority of cases caused by mutations in IL2RG, IL7RA, ADA, JAK3, RAG1, RAG2, or DCLRE1C. 1, 2 In contrast to severe CID, T-and B-cell development is not as severely impaired in CID. CID has been associated with hypomorphic mutations in severe CID-causing genes as well as mutations in several other genes: ZAP70, MHC class II deficiencies, PNP, ORAI-1, STIM1, NEMO, CARD11, and MALT1. [3] [4] [5] [6] [7] However, the etiology of many patients with CID remains unknown.
The IkB kinase (IKK) complex contains 2 structurally related catalytic subunits, IKKa and IKKb, and a regulatory subunit, IKKg/ NEMO. 8, 9 Null alleles of the X-linked gene encoding NEMO (IKBKG) cause incontinentia pigmenti in heterozygous females and are lethal in hemizygous males. 10 Hypomorphic alleles are compatible with life in males but cause immunodeficiency and accompanying developmental abnormalities of teeth, hair, or sweat glands in many patients. 3, 11, 12 Hypermorphic mutations in the gene encoding IkBa cause autosomaldominant ectodermal dysplasia with T-cell immunodeficiency, undetectable memory T cells, and absence of response to CD3-T-cell receptor activation. 13 The IKKa/b/NEMO complex, activated by antigen and other receptors, phosphorylates the IkB molecules, leading to subsequent NFkB nuclear translocation to activate transcription of genes involved in immune responses. 14 We report a homozygous nonsense mutation in IKBKB in 4 patients with CID from 2 unrelated families and compare and contrast our findings with those in 2 other recent reports of mutations in this gene. 15, 16 Patient, materials, and methods Abbreviated information is presented here. Details are provided in the supplemental Data, available on the Blood Web site.
Patients
All studies were performed with the approval of the Duke University Medical Center Institutional Review Board, and written informed consent of the patients' parents was collected in accordance with the Declaration of Helsinki. The patients were members of 2 unrelated consanguineous families. Select clinical features are presented in Table 1 , with further details available in the supplemental Data.
Immunologic phenotype analysis
Flow cytometry of peripheral blood leukocytes was performed with labeled antibodies. Lymphocyte proliferation was assessed as previously described. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.
Exome sequencing, alignment, and variant calling
Exome sequencing was performed in the Genomic Analysis Facility in the Center for Human Genome Variation at Duke University. Sequencing libraries were prepared from DNA extracted from patients' leukocytes using the Illumina TruSeq library preparation kit, following the manufacturer's protocol.
Establishment of Epstein-Barr virus cell lines
Epstein-Barr virus (EBV)-transformed B-cell lines were established from peripheral blood leukocytes, as previously described. 18 Cloning of full-length and mutant HuIKKb, transfection, and retroviral transduction
Wild-type full-length (FL-hIKKb) or R286X mutant IKKb cDNA, amplified from a wild-type human IKKb template (Addgene) with a forward primer 59-GTGAACCGTCAGAATTGATCT-39 and a reverse primer 59-gagtGtttaaacACATCATGAGGCCTGCTCCA-39 or 59-CggaattcTCAGGGGTGCCACATCAGCATCA-39, was cloned into the MIGR1 retroviral vector. Retroviral vectors were transfected into the Phoenix-Ampho cells to generate amphotropic retroviruses.
Cell stimulation, isolation of nuclear and cytoplasmic fractions, and immunoblot analysis EBV-transformed B cells, which were rested in Dulbecco's phosphate buffered saline at 37°C for 30 minutes, were stimulated with phorbol myristate acetate (PMA) (20 ng/mL) or anti-human CD40 (10 mg/mL, Biolegend) at 37°C for 10 or 20 minutes. Nuclear extracts and cytosolic or total cell lysates were subjected to standard immunoblotting analysis.
Real-time quantitative polymerase chain reaction
Total RNA from peripheral blood mononuclear cells and EBV-transformed B cells was used for real-time quantitative polymerase chain reaction analysis.
Statistical analysis
Two-tail Student t test was performed (*P , .05; **P , .01; ***P , .001; Figure 1 ). Figure 1) .
All patient T cells displayed normal responses to phytohemagglutinin, but low responses to pokeweed mitogen or concanavalin A were seen in 3 of them ( Figure 1A) . Strikingly, all patients' T cells failed to respond to candida or tetanus toxoid antigens or anti-CD3 stimulation ( Figure 1B-C) . Moreover, patients' CD4 T cells were impaired for T-cell receptor-induced CD25 and CD69 upregulation ( Figure 1D ). NK-cell function, tested in 1 patient from each family, was impaired in both patients (data not shown).
Whole exome sequencing on patients 1 and 2 representing the 2 unrelated families identified a single candidate nonsense homozygous variant in IKBKB (R286X). The other 2 patients and the parents carried the same homozygous and heterozygous variant, respectively (supplemental Figure 1C-D Contrary to in healthy controls and a heterozygous sibling, anti-N-or -C-terminal IKKb antibodies failed to detect any full-length or truncated IKKb in patients' peripheral blood mononuclear cells and EBV-transformed B-cell lines ( Figure 1E-F ) that was not caused by possible low quality of the antibody (supplemental Figure 1E) . Interestingly, NEMO was virtually undetectable, but IKKa was not obviously altered in patient samples ( Figure 1E-F) . Both IkKb and NEMO mRNA levels were considerably increased in patients' peripheral blood mononuclear cells ( Figure 1G ). Contrary to wildtype IKKb, IKKb(R286X) could not associate with either IKKa or NEMO when overexpressed in Phoenix-eco cells ( Figure 1H ).
Patients' EBV-transformed B cells displayed reduced IkBa phosphorylation and degradation and impaired nuclear accumulation of NFkB after stimulation with PMA, which activates the PKC-IKKNFkB pathway ( Figure 1I) . 19 Such defects were corrected after reconstitution with full-length but not IKKb(R286X), suggesting that IKKb(R286X) caused defective IkBa/NFkB activation in patient-derived B cells ( Figure 1J and supplemental Figure 1F) . Concordantly, expansion of patient's EBV-transformed B cells, which was slower in vitro than their sibling's or parents' counterparts, could be accelerated to wild-type levels when reconstituted with full-length, but not mutant, IKKb ( Figure 1J ). Interestingly, patient B cells expressing IKKb(R286X) expanded slower than cells expressing green fluorescence protein alone, suggesting that IKKb(R286X) exerted a dominant-negative function. At this time, it is unclear whether IKKb(R286X) may interfere with the residual IKKa/NFkB signaling in these cells.
Together, these observations indicate that IKKb protein is absent in the patients and that the C terminus of IKKb mediates its association with IKKa/NEMO, which may be important for the stability of itself and of NEMO, supporting that the nonsense mutation in IKBKB caused CID in these patients. Our results indicate that IKKb is not required for the development of T and B cells and show a novel cause of CID related to defects in the NFkB pathway. These findings highlight the diversity of phenotypes associated with mutations in different components of the NFkB pathway. For example, most patients with mutations in IKBKG had ectodermal dysplasia, 20 which was absent in our IKKb(R286X) patients even though they have almost undetectable NEMO. Interestingly, while this manuscript was in preparation/review, 2 other IKBKB mutations in CID patients were reported: one a duplication of exon 13 (IKBKB13Dup), 15 and the other Y107X nonsense mutation of IKBKB. 16 The clinical features of our patients were similar to those in the other 2 reports, with early infections with candida, gram-negative bacteria, viruses, and mycobacteria. The immunological features were also similar: They all have elevated numbers of naive T cells that were poorly activated by antigens and anti-CD3, low numbers of B cells that were also naive, and low numbers and function of NK cells. There was a paucity of CD45RO-positive T cells, Tregs, and g/d T cells. Similar to our study, mutant IKKb protein was undetectable and NEMO was decreased in IKBKB13Dup patients. 15 However, IKKa was not obviously decreased in our IKKb(R286X) patients but was severely decreased in the IKBKB13Dup patients. 15 The effect of IKKb(Y107X) mutation on IKKa and NEMO expression was not reported. 16 sequencing data; H.W. participated in functional studies; M.A. referred the patients and conducted immunologic investigations; R.E.P. performed extensive immunologic studies and contributed to manuscript preparation; J.L.R. contributed to data analysis and manuscript composition; D.B.G. oversaw the whole-genome sequencing and data analysis and contributed to the manuscript; R.H.B. designed the study, wrote the paper, and performed extensive immunologic evaluations; X.-P.Z. designed functional studies, analyzed data, and wrote the paper.
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